3/21/2023 6:46:57 AM
Beam Therapeutics Appoints Gopi Shanker As Chief Scientific Officer
2/28/2023 6:39:29 AM
Beam Therapeutics Q4 Loss Per Share $0.54 Vs Loss $0.95 Last Year
12/2/2022 6:38:22 AM
Beam Therapeutics Says FDA Has Lifted Clinical Hold On IND Application For BEAM-201
11/7/2022 7:06:32 AM
Beam Therapeutics Q3 Net Loss $109.6 Mln Or $1.56/Shr Vs Loss $28.1 Mln Or $0.42/Shr Last Year
8/9/2022 6:41:11 AM
Beam Therapeutics Q2 Net Loss $72.0 Mln Or $1.02/Shr Vs Loss Of $76.3 Mln Or $1.23/Shr Last Year
8/1/2022 4:46:22 PM
Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $100 Price Target
8/1/2022 6:41:29 AM
Beam Therapeutics Announces FDA Clinical Hold On BEAM-201 IND Application
5/9/2022 7:04:41 AM
Beam Therapeutics Q1 Net Loss $69.2 Mln Or $1.01/Shr Vs Loss $201.6 Mln Or $3.35/Shr Last Year
2/28/2022 5:03:42 PM
Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) FY22 Estimate To -6.29 From -3.71
2/28/2022 5:03:19 PM
Wedbush Is Lowering Beam Therapeutics Inc. (BEAM) Q4 22 Estimate To -1.63 From -0.96
2/28/2022 5:03:00 PM
Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) Q3 22 Estimate To -1.59 From -0.94
2/28/2022 5:02:43 PM
Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) Q2 22 Estimate To -1.55 From -0.91
2/28/2022 5:02:32 PM
Wedbush Is Lowering Beam Therapeutics Inc. (BEAM) Q1 22 Estimate To -1.53 From -0.91